Market Cap 1.59B
Revenue (ttm) 74.68M
Net Income (ttm) -644.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -863.36%
Debt to Equity Ratio 0.01
Volume 14,714,900
Avg Vol 22,240,307
Day's Range N/A - N/A
Shares Out 529.91M
Stochastic %K 94%
Beta 1.00
Analysts Sell
Price Target $6.79

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Address:
41 South Rio Grande Street, Salt Lake City, United States
ArmLee
ArmLee Aug. 3 at 9:45 PM
$RXRX Guys, I am smelling a BUY-OUT announcement by $LLY for some weird reasons. If that ever happens, what would be your price prediction? - just curious.
2 · Reply
GianNico15
GianNico15 Aug. 3 at 5:46 PM
$RXRX stay above $3.06 looking good from here
0 · Reply
916Investments
916Investments Aug. 3 at 3:52 PM
$RXRX interesting
0 · Reply
MarketPro
MarketPro Aug. 3 at 2:45 PM
$RXRX Chart Update:
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 2:41 PM
$RXRX Don’t you, Don’t you dare run before December 1st when all my 340k shares become LTI like 🚀🚀🚀😂🤣
0 · Reply
Lh2838
Lh2838 Aug. 3 at 2:39 PM
$RXRX The market for elite AI talent is extremely competitive. Someone like Dr. Hoifung Poon isn’t easily replaced. There may only be a handful of people in the world with his combination of: frontier AI experience, biomedical AI expertise, large-scale model development, and experience leading research teams. Companies like: * OpenAI * Google DeepMind * Microsoft * Meta * NVIDIA * Anthropic * Isomorphic Labs * Major pharmaceutical companies are all competing for a relatively small number of people who have experience building frontier AI models for biology and drug discovery. But he chose RXRX 😘
2 · Reply
TradingLittlePharma
TradingLittlePharma Aug. 3 at 2:38 PM
$RXRX We've been flat, but I believe we'll continue this ascending triangle. Back above 4 within 2 weeks is my estimate.
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 2:07 PM
$RXRX 🤔 my mind wanders to the 5 BILLION AI in healthcare fund☕️
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 1:53 PM
$AMLX Good Morning August ☕️ My Bio 💎 s $RXRX $SANA $TEM
0 · Reply
Spartangio
Spartangio Aug. 3 at 12:00 PM
$RXRX The facts are : BlackRock: increased. Vanguard: continues to hold a large position ARK: trimmed modestly but still holds ~34M shares The institutional data don't support the 'everyone is dumping' narrative
1 · Reply
Latest News on RXRX
Recursion Pharmaceuticals Transcript: AGM 2026

Jun 17, 2026, 2:00 PM EDT - 6 weeks ago

Recursion Pharmaceuticals Transcript: AGM 2026


Recursion to Participate in Upcoming Investor Conferences

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Recursion to Participate in Upcoming Investor Conferences


Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)

2026-05-07T09:29:09.000Z - 3 months ago

Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)


Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026


Recursion Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings release: Q1 2026


Recursion Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Quarterly report: Q1 2026


Recursion Pharmaceuticals Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Slides: Q1 2026


Recursion Announces Board Transition

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Recursion Announces Board Transition


Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing


Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing


PacBio appoints Gibson to Board of Directors

2026-03-05T13:44:59.000Z - 5 months ago

PacBio appoints Gibson to Board of Directors

PACB


Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:00 AM EST - 5 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025


Recursion Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:00 AM EST - 5 months ago

Recursion Pharmaceuticals Annual report: Q4 2025


Recursion Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:00 AM EST - 5 months ago

Recursion Pharmaceuticals Earnings release: Q4 2025


Recursion Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 8:00 AM EST - 5 months ago

Recursion Pharmaceuticals Slides: Q4 2025


What's Happening With RXRX Stock?

Dec 18, 2025, 11:05 AM EST - 8 months ago

What's Happening With RXRX Stock?


Recursion Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Transcript: Study Update


Recursion Pharmaceuticals Press release: Study Update

Dec 8, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Press release: Study Update


Recursion Pharmaceuticals Slides: Study Update

Dec 8, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Slides: Study Update


Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025


Recursion Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Quarterly report: Q3 2025


Recursion Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Earnings release: Q3 2025


Recursion Pharmaceuticals Slides: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Slides: Q3 2025


Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025


Recursion Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q2 2025


Recursion Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q2 2025


Recursion Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q2 2025


Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025


Recursion Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q1 2025


Recursion Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q1 2025


Recursion Pharmaceuticals Slides: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q1 2025


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference


Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024


Recursion Pharmaceuticals Annual report: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Annual report: Q4 2024


Recursion Pharmaceuticals Earnings release: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q4 2024


Recursion Pharmaceuticals Slides: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q4 2024


Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital


Recursion Pharmaceuticals Slides: FY 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: FY 2025


Recursion Pharmaceuticals Transcript: Status Update

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update


Recursion Pharmaceuticals Slides: Status Update

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Slides: Status Update


Recursion Pharmaceuticals Transcript: Status Update

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update


Recursion Pharmaceuticals Press release: Status Update

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Press release: Status Update


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q3 2024


Recursion Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q3 2024


Recursion Pharmaceuticals Slides: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q3 2024


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 4, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


Recursion Pharmaceuticals Proxy statement: Proxy Filing

Aug 28, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing


ArmLee
ArmLee Aug. 3 at 9:45 PM
$RXRX Guys, I am smelling a BUY-OUT announcement by $LLY for some weird reasons. If that ever happens, what would be your price prediction? - just curious.
2 · Reply
GianNico15
GianNico15 Aug. 3 at 5:46 PM
$RXRX stay above $3.06 looking good from here
0 · Reply
916Investments
916Investments Aug. 3 at 3:52 PM
$RXRX interesting
0 · Reply
MarketPro
MarketPro Aug. 3 at 2:45 PM
$RXRX Chart Update:
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 2:41 PM
$RXRX Don’t you, Don’t you dare run before December 1st when all my 340k shares become LTI like 🚀🚀🚀😂🤣
0 · Reply
Lh2838
Lh2838 Aug. 3 at 2:39 PM
$RXRX The market for elite AI talent is extremely competitive. Someone like Dr. Hoifung Poon isn’t easily replaced. There may only be a handful of people in the world with his combination of: frontier AI experience, biomedical AI expertise, large-scale model development, and experience leading research teams. Companies like: * OpenAI * Google DeepMind * Microsoft * Meta * NVIDIA * Anthropic * Isomorphic Labs * Major pharmaceutical companies are all competing for a relatively small number of people who have experience building frontier AI models for biology and drug discovery. But he chose RXRX 😘
2 · Reply
TradingLittlePharma
TradingLittlePharma Aug. 3 at 2:38 PM
$RXRX We've been flat, but I believe we'll continue this ascending triangle. Back above 4 within 2 weeks is my estimate.
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 2:07 PM
$RXRX 🤔 my mind wanders to the 5 BILLION AI in healthcare fund☕️
0 · Reply
LoveRetailFroth
LoveRetailFroth Aug. 3 at 1:53 PM
$AMLX Good Morning August ☕️ My Bio 💎 s $RXRX $SANA $TEM
0 · Reply
Spartangio
Spartangio Aug. 3 at 12:00 PM
$RXRX The facts are : BlackRock: increased. Vanguard: continues to hold a large position ARK: trimmed modestly but still holds ~34M shares The institutional data don't support the 'everyone is dumping' narrative
1 · Reply
Brodman
Brodman Aug. 3 at 11:01 AM
$RXRX More RED AHEAD....ARK dumping and ZERO performance mean one thing....going much lower. Will not be one of the survivors, not the management operates.
0 · Reply
PuPuPu
PuPuPu Aug. 3 at 10:44 AM
$RXRX Why $RXRX is doomed to fail: ​Insane Compensation: Just granted 3.23M RSUs to 24 new employees (avg 134k shares per person). ​Zero Revenue: Burning cash to fund these ridiculous signing bonuses. ​Smart Money is Leaving: Cathie Wood (ARK) continues to dump her shares non-stop. ​A company that dilutes its shareholders this aggressively just to throw money at new hires will inevitably bankrupt itself. Stop funding their greed.
1 · Reply
Bulltrader988
Bulltrader988 Aug. 2 at 8:12 PM
$RXRX Wednesday pre market 👃👀
0 · Reply
Bulltrader988
Bulltrader988 Aug. 2 at 7:15 PM
$RXRX And another 13G filled on 2026-07-31.... Vanguard Capital Management 26,744,129 shares = 5.09 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1601830/000210011926001441/xslSCHEDULE_13G_X02/primary_doc.xml
0 · Reply
Bulltrader988
Bulltrader988 Aug. 2 at 7:13 PM
$RXRX 13G filled on 2026-07-31... Vanguard Portfolio Management 31,369,274 shares = 5.97 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1601830/000210012126000994/xslSCHEDULE_13G_X02/primary_doc.xml
1 · Reply
Floridaorange
Floridaorange Aug. 2 at 6:19 AM
$RXRX The Q2 call is scheduled for Wednesday, 5 August 2026, before the market opens, with the webcast at 8:00 a.m. ET. The best setup is: credible REC-4881 activity; an FDA-pathway discussion underway; REC-1245 still escalating without an identified early safety failure; several partnered programmes capable of producing milestones; substantially reduced operating expenses; significant cash; and multiple second-half decisions approaching.
0 · Reply
The_Claw
The_Claw Jul. 31 at 9:09 PM
$RXRX The number of bears here is encouraging.
1 · Reply
Brodman
Brodman Jul. 31 at 4:01 PM
$RXRX Insiders and Nvidia dumping shares tells me it's going lower regardless what a few institutional have done. Cathie Wood will be dumping soon, she is taking a BEATING.
0 · Reply
ayedude
ayedude Jul. 31 at 3:57 PM
$RXRX when stocky go uppy??
1 · Reply
Spartangio
Spartangio Jul. 31 at 3:47 PM
$RXRX Correct now So at least 31 mln.. Vanguard Capital Management LLC: 26,744,129 shares (5.09%) * Vanguard Portfolio Management LLC: 31,369,274 shares (5.97%)
0 · Reply
PuPuPu
PuPuPu Jul. 31 at 3:31 PM
$RXRX There is no positive news, executive pay is over the top, and insider selling continues unabated. How can the stock price possibly rise under these conditions?
1 · Reply
Spartangio
Spartangio Jul. 31 at 2:51 PM
$RXRX VANGUARD CAPITAL MANAGEMENT 26,744,129 shares also increased
0 · Reply